Instil Bio, Inc. (TIL)
5.795
-0.28
(-4.69%)
USD |
NASDAQ |
Nov 16, 15:37
Instil Bio Enterprise Value : 58.72M for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 58.72M |
| November 12, 2026 | 59.81M |
| November 11, 2026 | 60.28M |
| November 10, 2026 | 60.55M |
| November 09, 2026 | 61.37M |
| November 06, 2026 | 63.81M |
| November 05, 2026 | 64.89M |
| November 04, 2026 | 64.89M |
| November 03, 2026 | 62.72M |
| November 02, 2026 | 61.91M |
| October 30, 2026 | 63.61M |
| October 29, 2026 | 63.78M |
| October 28, 2026 | 63.54M |
| October 27, 2026 | 57.09M |
| October 26, 2026 | 55.26M |
| October 23, 2026 | 57.09M |
| October 22, 2026 | 56.15M |
| October 21, 2026 | 56.62M |
| October 20, 2026 | 57.77M |
| October 19, 2026 | 56.76M |
| October 16, 2026 | 57.57M |
| October 15, 2026 | 59.06M |
| October 14, 2026 | 57.84M |
| October 13, 2026 | 59.40M |
| October 12, 2026 | 62.11M |
| Date | Value |
|---|---|
| October 09, 2026 | 63.20M |
| October 08, 2026 | 61.98M |
| October 07, 2026 | 64.28M |
| October 06, 2026 | 64.18M |
| October 05, 2026 | 64.62M |
| October 02, 2026 | 66.45M |
| October 01, 2026 | 66.56M |
| September 30, 2026 | 66.59M |
| September 29, 2026 | 65.91M |
| September 28, 2026 | 65.23M |
| September 25, 2026 | 66.11M |
| September 24, 2026 | 65.78M |
| September 23, 2026 | 66.56M |
| September 22, 2026 | 65.84M |
| September 21, 2026 | 65.44M |
| September 18, 2026 | 65.57M |
| September 17, 2026 | 66.39M |
| September 16, 2026 | 66.18M |
| September 15, 2026 | 66.39M |
| September 14, 2026 | 68.01M |
| September 11, 2026 | 67.54M |
| September 10, 2026 | 67.40M |
| September 09, 2026 | 68.90M |
| September 08, 2026 | 70.52M |
| September 04, 2026 | 68.90M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.335B |
| Alnylam Pharmaceuticals, Inc. | 21.50B |
| Anika Therapeutics, Inc. | 160.67M |
| Savara, Inc. | 854.40M |
| Arrowhead Pharmaceuticals, Inc. | 6.959B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.299M |
| Total Expenses (Quarterly) | 4.299M |
| EPS Diluted (Quarterly) | -0.6339 |
| Earnings Yield | -77.17% |
| Normalized Earnings Yield | -77.97 |